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In this issue (page 586),
1 Linda Perron and colleagues
question whether the recent decline in age-standard-
ized prostate cancer mortality rates in Quebec could be
attributed to screening with the serum prostate-specific
antigen (PSA) test. By comparing the change in the inci-
dence rate of prostate cancer between 1989 and 1993 with
the change in the prostate cancer mortality rate between
1995 and 1999 in 15 birth cohorts, and in 15 regions of
Quebec, the authors have elegantly shown that increased
screening efforts with the PSA test were not correlated
with the subsequent declining mortality rate.
PSA-based screening for prostate cancer remains a con-
troversial issue. The availability of presumably valid screen-
ing tests and the potential success of curative treatment op-
tions such as radical prostatectomy have prompted some
health authorities in the United States to advocate prostate
cancer screening in men who ask about the PSA test.2,3 On
the other hand, the Canadian Urological Association and
most health authorities in the European Union still dis-
courage the practice of prostate cancer screening.4,5
In the United States, following several decades of gradu-
ally increasing death rates that reached their peak in 1993,
the prostate cancer mortality rate began to decline steadily
in the late 1990s. Since 1993, the prostate cancer mortality
rate has decreased by 17.6%, at an annual mean rate of
4.4% between 1994 and 1997.3,6 In Canada, the age-stan-
dardized prostate cancer mortality rate declined by 9.6%
between 1991 and 1996.7 Some have already suggested that
this trend provides evidence for the effectiveness of screen-
ing with the PSA test,8 however, the significance of the data
concerning the decline in prostate cancer mortality is sub-
ject to differing interpretations.9–11
Many physicians consider that the application of the PSA
test may not be the main reason for the decline in prostate
cancer mortality. The reported decline may be the result of
increased use of curative treatment options in cancers diag-
nosed by digital rectal examination (DRE) before the advent
of PSA screening and the availability of improved treatment
options for advanced prostate cancer, such as the early appli-
cation of luteinizing hormone-releasing hormone (LHRH)
agonists. Changes in diet and lifestyle12,13 and improvements
in environmental conditions14 may also have been responsible
for improved outcomes in recent cohorts. The observation
that mortality rates for prostate cancer have also declined in
England and Wales, countries in which prostate cancer
screening was only infrequently applied in that same period,
seem to support these assumptions.15 Last, misclassification of
deaths, that is “attribution bias” or the incorrect labelling of
deaths from other causes as being death from prostate cancer,
may account for some of the reported changes as well.16
Indirect evidence for a possible beneficial effect of
prostate cancer screening came from the urology department
of the University of Innsbruck, Austria, where, in contrast to
other parts of Austria, the PSA test had been made freely
available to the population in 1993 and acceptance of testing
was high.17 The investigators reported 33% fewer prostate
cancer deaths than expected in the Innsbruck area between
1996 and 1999 in men aged 40–79 years. The authors con-
cluded that the policy of making the PSA assay universally
available to the population (and at no cost) might have re-
duced the prostate cancer mortality rate in that population.17
In the Innsbruck study, however, ascribing observed
changes in mortality to widespread PSA testing done only
3–6 years earlier is dubious. By comparison, in breast cancer
screening an interval of at least 9 years was expected before
any impact of an effective breast cancer screening program
with mammography could be seen in the population.18 As
shown by Perron and colleagues,1 the observed changes in
the prostate cancer mortality rates so soon after the onset of
widespread PSA testing are unlikely to be the result of in-
creased screening efforts given the long natural course of
most prostate cancers. If a beneficial effect of screening for
prostate cancer with the PSA blood test is present at a popu-
lation level, it will only begin to appear when the mean lead
time of prostate cancer (the time by which diagnosis is ad-
vanced by screening) and the mean time from the clinical
diagnosis to prostate cancer death have passed, that is, at
least a decade after the initiation of screening efforts.11,19
The definitive answer to the question of whether PSA-
based screening for prostate cancer leads to a decline in dis-
ease-specific mortality lies in the careful performance and
completion of randomized controlled trials (RCTs). In such
trials, following randomization, the screened group and the
control group would be similar with respect to baseline
characteristics, biases and confounders would be prevented,
and changes in cause-specific mortality could be attributed
to the application of the screening tests and early treatment.
To date, only one RCT has reported an important primary
end point of prostate cancer screening, namely, the prostate
cancer death rate.20 This trial in Quebec showed that PSA-
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based screening for prostate cancer resulted in a reduction
in prostate cancer mortality of up to 70% in those subjected
to screening compared with those who were not.20
This study has been criticized, because the reseachers ran-
domly allocated men to study groups before they agreed to
take part in the RCT. In fact, only 23% of the trial popula-
tion were willing to participate. The resulting decrease in sta-
tistical power could not be resolved, as the authors attempted,
by transferring men from the control group who sponta-
neously sought a PSA test to the treatment arm of the trial or
by the reverse manoeuvre for men in the treatment group
who refused screening. Both ploys further compromised and
invalidated the randomization.21 The study has also been
faulted for the long lag time between randomization and
screening — on average, 3 years. Given that only men with-
out a diagnosis of prostate cancer could participate in the
trial, those who were not screened at the time of analysis were
at risk of prostate cancer mortality for a substantially longer
period than those men in the screened group.22
Large-scale RCTs with the prostate cancer death rate as
the primary end point were also begun in Europe and the
United States in the early 1990s, namely, the European
Randomized study of Screening for Prostate Cancer (ER-
SPC) and the Prostate, Lung, Colorectal, Ovarian cancer
(PLCO) screening trial respectively. Therefore, a final an-
swer to the question of whether screening for prostate can-
cer is truly beneficial at a population level can only be an-
swered when these trials have been completed and properly
analyzed, that is, not until the middle of the present decade.
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